Tyrosinase-related protein (TRP)-2 is not only expressed on glioma cells, but is naturally processed and presented by their surface MHC molecules and is recognized by TRP-2-specific cytotoxic T cells. After active immunotherapy, we detected TRP-2-specific cytotoxic T lymphocyte (CTL) activity in patients' peripheral blood mononuclear cells (PBMC). Tumor cells from postvaccination resections showed significantly lower TRP-2 expression and higher sensitivity to carboplatin and temozolomide than those autologous cell lines from prevaccination resections in two patients who demonstrated CTL response to TRP-2. One of two patients underwent treatment with temozolomide after recurrence and responded dramatically. TRP-2-transfected cell line (TRP-2-U373) resulted in significant drug resistance to carboplatin and temozolomide compared to wild-type U-373 (W-U373). There was no significant difference, however, in the mRNA expression of other common drug resistance related proteins, such as BCRP-1, MGMT, MDR-1, MRP-1 and MRP-3, after TRP-2 transfection. TRP-2-U373 tumor cells were immunoselected by a TRP-2-specific CTL line. The immunoselected cells (IS-TRP-2-U373) demonstrated significantly increased sensitivity to carboplatin and temozolomide compared to TRP-2-U373. For the first time, we provide evidence that immunological targeting of tumor-associated antigen TRP-2 significantly increases sensitivity to chemotherapy.
Introduction
Chemotherapy in combination with surgery and radiation remains the primary treatments for glioblastoma. One of the major limitations of this approach is that malignant cells are either intrinsically resistant to chemotherapy or are able to acquire resistance during treatment. Over the past decade, analysis of the drug resistance of brain tumors has become a topic of much research interest, and there has been some progress in our understanding of the molecular mechanisms by which brain tumor cells develop a drug-resistant phenotype (Bredel and Zentner, 2002) , although no practical strategy has been developed to improve sensitivity to chemotherapy consistently.
The development of immune-based therapies for various cancers including malignant glioma has been heralded with much hope and optimism, although the ability of current cancer immunotherapies by themselves to elicit objective clinical benefit for most patients has not been realized (Rosenberg et al., 1998; Lee et al., 1999) . While current cancer vaccines reliably elicit tumor-reactive cytotoxic T lymphocytes (CTLs) in most patients (Rosenberg et al., 1998; Lee et al., 1999; Bodey et al., 2000) , the reasons underlying the general clinical failure of cancer vaccines are unknown. One possibility is that the rate of antitumor CTL killing in cancer patients may be too slow to keep pace with rapidly growing and mutating tumors in situ. Thus, research into a synergy of immunotherapies with more conventional treatments has generated increasing interest (Nair et al., 2003; Nowak et al., 2003; Wheeler et al., 2004) .
In the past decade, the identification of genes encoding tumor antigens that CTLs can recognize has been extensively pursued (Rosenberg et al., 1998; Wang and Rosenberg, 1999) . Most of the genes that have been identified are from melanomas and belong to a family of genes that encode cancer/testis antigens or melanoma differentiation antigens (Rosenberg et al., 1998; Wang and Rosenberg, 1999) . The antigenic peptides of these gene products that CTLs can recognize in an MHC class I restricted manner have also been identified, and some of them have been used as a peptide-based cancer vaccine in clinical trials for patients with melanomas (Rosenberg et al., 1998; Wang and Rosenberg, 1999) . Our previous study demonstrated that TRP-2 was not only expressed on glioma cells but was also naturally processed and presented by their surface MHC molecules. After active immunization with tumor-lysate pulsed dendritic cells (DCs), TRP-2-specific CTLs were induced in the peripheral blood of patients who were HLA-A2 þ and whose tumors expressed TRP-2 antigen, suggesting that TRP-2 is an immunotherapeutic target in human malignant glioma (Liu et al., 2003) .
Recently, there were some reports that TRP-2 overexpression was associated specifically with resistance to DNA-damaging drugs and radiation treatment (Chu et al., 2000; Pak et al., 2000 Pak et al., , 2001 Pak et al., , 2004 . We also reported recently that compared to patients receiving either chemotherapy or vaccinations alone, glioblastoma patients who received chemotherapy after active immunological DC-based vaccination experienced slower tumor progression and longer survival times . In all of the GBM patients receiving postvaccine chemotherapy, CD8 þ T-cell Receptor Excision Circles (TRECs) predicted significantly longer chemotherapeutic responses, revealing a strong link between tumor chemosensitivity and the predominant T-cell effectors in GBM . Based on the previous report and our clinical observations, we hypothesized that TRP-2 may play an important role in the synergy between chemotherapy and immunotherapy. TRP-2 is a highly immunogenic tumor-associated antigen resulting in TRP-2-specific CTL induction by tumor lysate-pulsed DC vaccinations. TRP-2, however, may also mediate glioma drug resistance. Recurrent glioblastoma that has escaped TRP-2-specific CTL killing after immunotherapy may, therefore, be more sensitive to chemotherapy. We propose that therapeutic vaccination works in a synergy with subsequent chemotherapy to elicit tangible clinical benefits for GBM patients by sensitizing tumor cells to drugs that damage DNA after CTL immune selection has depleted drug-resistant tumor cells.
Results

Increased recurrent tumor cell drug sensitivity after active immunotherapy in GBM patients
After active immunotherapy, TRP-2 CTL activity was detected by ELISPOT assay in two patients' PBMC (pt. 81 and pt. 11) (Figure 1 ). We further investigated TRP-2 expression, CTL recognition and tumor cell drug resistance in the same two patients pre-and post vaccination. As shown in Figure 2a , the recurrent tumor cells (R) of both pt. 81 and pt. 11 after vaccination expressed significantly lower levels of TRP-2 mRNA than that of primary tumor cells (P) derived from the same patients before vaccination.
Furthermore, TRP-2-reactive CTL recognition of the recurrent tumor cells, including 11-R and 81-R, was significantly reduced compared to that of autologous primary tumor cells (Figure 2b ). This finding correlated with low levels of recurrent tumor cell TRP-2 expression, since there was no significant difference in HLA-A2 expression between the primary and recurrent tumor cells derived from the same patient (data not shown). As shown in Figure 3 , the recurrent tumor cells from both pt. 81 and pt. 11 showed enhanced sensitivity to carboplatin and temozolomide at lower concentrations than that displayed by primary tumor cells from the same patients before vaccination. One of two patients (pt. 11) underwent treatment with temozolomide after Figure 1 TRP-2 180-188 -specific CTL in patients' PBMC pre-and postvaccination. PBMC from 1 week before treatment and 2 weeks after third treatment were used in this experiment. ELISPOTs were performed according to the manufacturer's instructions (see Materials and methods). The results shown here are means from triplicate wells. The asterisks indicate a significant increase in the numbers of spots in the postvaccination PBMC over the respective prevaccination PBMC (Po0.01) after the background (unpulsed T2) value was subtracted from the matching T2 þ TRP-2 value. * in the figure denoted Po0.05 compared to autologous PBMC of prevaccination TRP-2 overexpression increased drug resistance to temozolomide and carboplatin in a GBM cell line
In order to examine the effects of TRP-2 on drug resistance in glioma cells, GBM cell line U373 (W-U373) was transfected with TRP-2 plasmid. Transfected cell lines consisting of a negative control clone (CON-U373, i.e. transfected with vector only) and an overexpression clone (TRP-2-U373) were established after G418 selection. As shown in Figure 5 , TRP-2 mRNA and protein were overexpressed in the TRP-2-U373 clone, while there were very low levels of TRP-2 expression in the W-U373 and CON-U373 cells. TRP-2-U373 cells were examined for resistance to carboplatin and temozolomide. As shown in Figure 6 , TRP-2 overexpression significantly increased drug resistance to both carboplatin and temozolomide. There was no significant difference, however, in the mRNA expression of other common drug-resistance-related proteins, such as BCRP-1, MGMT, MDR-1, MRP-1 and MRP-3, after TRP-2 transfection ( Figure 7 ).
Enhanced drug sensitivity in tumor cells after immunoselection with TRP-2-reactive CTLs
In our previous report, glioma cells were found to express the TRP-2 antigen, which was naturally processed and presented by surface MHC molecules. TRP-2-specific CTL clone (MR7) recognized TRP-2-positive tumor cells in a HLA class I restricted manner (Liu et al., 2003) . Recognition of tumor cells depends on antigen and MHC expression. As shown in Figure 8a , CTL clone MR7 cells can efficiently recognize TRP-2-U373 tumor cells (mel624.38 cells as positive control), while there was no significant IFN-g release when CTLs were incubated with W-U373 and CON-U373. Furthermore, there was no difference in HLA-A2 expression among the three lines (data not shown). On the basis of these findings of increased CTL-mediated lysis of tumor cells after TRP-2 transfection, we hypothesized that the selection by the CTLs may result in the elimination of those tumor cells displaying TRP-2 overexpressionmediated drug resistance. If this hypothesis were correct, the resulting tumor cell population that escaped CTL killing would then be more susceptible to the cytotoxic activity of carboplatin and temozolomide. To test this hypothesis, CTL immunoselected populations (IS-TRP-2-U373 and IS-mel624.38) were created by coculturing TRP-2 CTLs with TRP-2-U373 or mel624.38 cells at a low ratio of effector cells to target cells (1 : 2). As shown in Figure 8 , after immunoselection, TRP-2 mRNA expression and its recognition by CTLs in both IS-TRP-2-U373 and IS-mel624.38 were significantly decreased compared to the control group (respective tumor cell lines preimmunoselection). We then compared the drug resistance of the population that escaped CTL killing (IS-TRP-2-U373) with that of both W-U373 and TRP-2-U373. As shown in Figure 9a and b, drug resistance Targeting of TRP-2 by CTL to enhance chemotherapy sensitivity G Liu et al was completely absent in the CTL escape population compared with TRP-2-U373. Of interest, the CTL escape population was more sensitive to carboplatin and temozolomide than were the W-U373 cells. Very similar results were also found in mel624.38 cells after immunoselection ( Figure 9c and d) ; however, there was no change in drug sensitivity after TRP-2 CTLs were cocultured with either W-U373 or CON-U373 (data not shown).
Discussion
In this study, we found that TRP-2-specific CTL was induced in patients' PBMC after active immunotherapy.
After vaccination, TRP-2 expression in two patients' recurrent tumor cell lines was significantly decreased. Furthermore, dramatic clinical response was observed in one patient who was treated with temozolomide after DC vaccination, in which TRP-2-specific CTLs were induced by immunotherapy. We demonstrated that TRP-2 overexpression significantly increased resistance to carboplatin and temozolomide without affecting the Targeting of TRP-2 by CTL to enhance chemotherapy sensitivity G Liu et al expression of common proteins related to drug resistance. After specific CTL immunoselection, IS-TRP-2-U373 tumor cells displayed high sensitivity to carboplatin and temozolomide. Our findings suggest that TRP-2 could be a powerful molecule linking chemotherapy and immunotherapy. This finding suggests a new strategy to improve chemotherapy sensitivity by targeting drugresistant-related tumor antigens.
Temozolomide is a new oral alkylating agent that is widely used for high-grade gliomas (Yung, 2001) . The cytotoxicity of temozolomide is primarily due to the formation of O 6 -methylguanine in DNA, which mispairs with thymine during the next cycle of DNA replication (Denny et al., 1994) . Subsequent futile cell cycles of DNA lead to mismatched repairs and results in cancer cell death (D'Atri et al., 1998) . Our study showed that TRP-2 overexpression cell line TRP-2-U373 increased resistance to both carboplatin and temozolomide. This finding was consistent with a previous report that TRP-2 overexpression increased specific resistance to DNAdamage drugs including carboplatin and methotrexate in melanoma (Chu et al., 2000) . In general, multidrug resistance (MDR) is a serious problem associated with chemotherapy. MDR occurs when cancer cells acquire crossresistance to a variety of structurally unrelated cancer chemotherapeutic agents after selection for resistance to a single anticancer agent (Gottesman and Pastan, 1993) . Current available data generated from investigations in cell lines and tumor samples suggest that resistance to temozolomide is significantly linked to O 6 -methylguanine-DNA methyltransferase (MGMT)-mediated DNA repair in high-grade gliomas, primitive neuroectodermal tumors and ependymomas (Bredel and Zentner, 2002) . After TRP-2 transfection, however, we found no significant change in MDR-1, MRP-1, MRP-3, BCRP-1 or MGMT mRNA expression in a glioma cell line, which indicated that TRP-2 may play a central role in increasing resistance to carboplatin and temozolomide.
Our previous studies have shown that melanomaassociated antigens, such as TRP-2, MAGE-1 and gp100 are not only expressed on glioblastoma tumor cells but also may be naturally processed and recognized by cytotoxic T-cells in an MHC class I restricted manner (Liu et al., 2003 (Liu et al., , 2004b . TRP-2 may be a unique target molecule for cancer vaccines because TRP-2 expression is not only a highly immunogenic tumor antigen but is also associated with chemotherapy resistance. TRP-2 was expressed in most established and primary cultured glioblastoma cells that have been tested (Chi et al., 1997; Liu et al., 2003) . TRP-2 CTLs were induced by DC-pulsed tumor lysate vaccination (Liu et al., 2003) .
TRP-2 overexpression has been shown to mediate resistance to treatments that evoke DNA damage (Chu et al., 2000; Pak et al., 2001) . Melanoma cells that overexpressed TRP-2 generated resistance not only to chemotherapeutic drugs but also to X-ray-and ultraviolet (UV)-radiation-induced apoptosis (Nishioka et al., 1999) . This indicates that TRP-2 protects against apoptosis. Although carboplatin and temozolomide induce cytotoxicity by distinct mechanisms, both of them ultimately induce DNA damage. This hypothesis was supported by the finding that TRP-2 overexpression in melanoma did not confer resistance to taxol, which acts by stabilizing microtubules, independent of DNA damage. Recently, it was also reported that MEK and Targeting of TRP-2 by CTL to enhance chemotherapy sensitivity G Liu et al p38 pathways are involved in the regulation of TRP-2 expression in cultured malanocytes (Fang et al., 2001) . The mechanism of drug-and radiation resistance associated with TRP-2 overexpression may be mediated by activating the ERK/MAPK pathway (Pak et al., 2004) . The clinical efficacy of therapeutic vaccination for any human tumor remains controversial because consistent tumor destruction or extended survival is not observed in most vaccinated cancer patients (Rosenberg et al., 1998; Lee et al., 1999) . In contrast, current cancer vaccines reliably elicit tumor-reactive CTLs in most patients (Rosenberg et al., 1998; Lee et al., 1999; Bodey et al., 2000) . Consistent with this notion, it was previously reported that therapeutic vaccination of GBM patients with autologous tumor antigen-pulsed DCs is sufficient to elicit antigen-specific tumor-reactive CTL activity and CD8 þ T-cell infiltration into tumors in situ (Yu et al., 2001 ). Specifically, TRP-2 and other tumor-antigen-specific CTLs, such as HER-2, MAGE-1 and gp100, were induced after DC vaccinations in our clinical trials (Liu et al., 2003; Yu et al., 2004) . The reasons underlying tumor recurrence despite CTL induction by cancer vaccines are unclear, but one possibility is that tumor cells escape from CTLs by antigen loss through immunoselection and immunediting processes (Dunn et al., 2002; Khong and Restifo, 2002) . Therefore, the clinical insufficiency of cancer vaccines and the effects of immunoselection on tumor evolution highlight the need to investigate a potential synergy between immunotherapy and other therapies.
The results presented here are consistent with a previous report that showed that CTL-resistant tumor cells exhibited higher drug sensitivity (Fisk and Ioannides, 1998) . TRP-2-U373 tumor cells were immunoselected by a TRP-2-recognizing CTL clone MR7, and the IS-TRP-2-U373 cells displayed significantly higher drug sensitivity. Similar to in vitro immunoselection, tumor cells derived from vaccinated patients with recurrences who elicited significant TRP-2 CTL response after vaccination demonstrated lower TRP-2 expression and greater sensitivity to carboplatin and temozolomide. Most importantly, one of two patients underwent treatment with temozolomide after recurrence and responded dramatically. Our study demonstrated the potential of current active immunotherapy to elicit fundamental physiological changes in GBM tumors, thereby improving sensitivity to chemotherapy.
Together, our findings suggest a possible molecular mechanism to explain the synergistic effects of immunotherapy followed by chemotherapy, and may provide a new strategy to improve chemotherapy sensitivity by targeting drug resistance. In this case, it is important to highlight that TRP-2 does not appear to be required for the development of all forms of drug resistance in tumor cells. Common drug-resistance proteins, such as MDR-1 Targeting of TRP-2 by CTL to enhance chemotherapy sensitivity G Liu et al and MRPs, could be utilized as immunotherapeutic targets to improve chemotherapy sensitivity. Recently, a HLA-A24-restricted epitope derived from MRP-3 has been identified (Yamada et al., 2001) . In this context, it will be important to determine whether immune responses to other drug-resistance modifiers can similarly influence chemotherapeutic efficacy in human cancer.
Materials and methods
Tumor specimens and primary tumor cell line culture
Brain tumor specimens from patients were obtained from the Brain Tumor Registry after being reviewed and released by a pathologist in the operating room. Independent pathologists classified the tumors by type and grade in accordance with the WHO histological typing of central nervous system tumors. All tumor specimens were obtained from patients who had signed informed consent forms. IRB-certified technicians processed the glioma tissues under sterile conditions in a laminar flow hood. Tumor cells were recovered from FicollHypaque gradients (Invitrogen, Carlsbad, CA, USA), washed in tissue culture medium and aliquoted for tissue culture or for cryopreservation in a Cryomed. For the establishment of the primary tumor cell line culture, tumor cells were seeded in a flask in the following culture medium: Ham's F-12/DMEM with high glucose (Irvine scientific, Santa Ana, CA, USA), 10 mM HEPES (Invitrogen), 0.1 mg/ml Gentamicin (Invitrogen) and 10% heat-inactivated FBS (Irvine Scientific). The cultured cells were maintained for 3-4 passages.
Reagents
Melanoma cell line 624.38 was kindly provided by the National Cancer Institute (Bethesda, MD, USA). Temozolomide was kindly supplied by the Schering-Plough Research Institute (Kenilworth, NJ, USA) and was dissolved in DMSO (Sigma Chemical Co., St Louis, MO, USA) at 100 mM stock solution. Carboplatin was purchased from Sigma Chemical Co. and was dissolved in H 2 O at 10 mM stock solution.
Establishment of TRP-2-transfected U373
TRP-2 expression plasmid pCMVDTS was kindly provided by Dr Shigeki Shibahara (Tohoku University, Miyagi, Japan), which includes the entire TRP-2 open reading frame (Yokoyama et al., 1994) that was cloned into the pCMV vector (Invitrogen, Carlsbad, CA, USA) and transfected into U373 cells (ATCC, Manassas, VA, USA) using Lipofectamine 2000 (Invitrogen). Transfected cells were selected with 800 mg/ml geneticin (Invitrogen) for more than 2 weeks. Cells resistant to geneticin were individually subcloned and expanded in culture.
RNA isolation and cDNA synthesis
Total cellular RNA was extracted using a RNA4PCR kit (Ambion, Austin, TX, USA) according to the manufacturer's protocol. For cDNA synthesis, B1 mg total RNA was reversetranscribed into cDNA using random oligo dT and reverse transcriptase. cDNA was stored at À201C for PCR and realtime quantitative PCR.
Real-time quantitative RT-PCR
Dual-color, real-time quantitative RT-PCR was performed using the icycler (Bio-Rad, Hercules, CA, USA). Targeting gene primers and probes (Operon, Alameda, CA, USA) were designed to span exon-intron junctions to prevent amplification of genomic DNA. Their probes were labeled with Texas Red. The predesigned b-actin primer/probe labeled by a FAM kit was used as an internal control and was purchased from Applied Biosystems (Foster City, CA, USA). A comparative threshold cycle was used to determine targeting genes and b-actin gene expression relative to the no-sample control (calibrator). The mRNA expression level was normalized by bactin expression (Saha et al., 2001; Monney et al., 2002) .
The 
Western Blot
Samples were extracted with buffer containing 1% Triton X-100, 150 mM NaCl, 50 mM Tris (pH 7.5) and 1 mM PMSF. The cell debris was removed by centrifugation at 14 000 g for 20 min, the supernatant was subjected to SDS-PAGE, and 20 mg protein extracts were loaded on a 10% polyacrylamide gel (Bio-Rad, Hercules, CA, USA). Electrophoretic transfer to nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ, USA) was followed by immunoblotting with primary antibodies directed against an exon-8-encoded peptide (anti-PEP-8) of the human TRP-2 protein, kindly provided by Dr VJ Hearing (National Institutes of Health, Bethesda, MD, USA) or a mouse IgG1 anti-b-tubulin (Sigma). This was followed by hybridization with a peroxidase-linked anti-rabbit or mouse IgG antibody (Amersham Bioscience). The signal was detected by chemiluminescence using an ECL detection system (Amersham Bioscience) and hyperfilm ECL (Amersham Bioscience).
Drug cytotoxicity assay
The number of viable cells following drug treatment was assessed using a WST-1 Cell Proliferation Assay (Roche, Indianapolis, IN, USA). Briefly, 1 Â 10 4 cells/well were plated in 96-well plates, allowed to attach overnight and then administered chemotherapeutic agents at various concentrations for 48 h. At 4 h prior to harvest, 20 ml/well of the reagent WST-1 was added and incubated for 1.5 h at 371C. An increase in the number of viable cells resulted in an increase in the overall activity of mitochondrial dehydrogenases in the sample with an ensuing increase in formazan dye formation. The quantity of formazan dye was quantified by measuring the optical density of the dye solution at 450 nm with a scanning multiwell spectrophotometer (Molecular Devices, Sunnyvale, CA, USA) using 890 nm as the internal reference (Liu et al., 2004a) . All results in the study were based on at least five parallel measurements each time, and each measurement was repeated in up to three independent experiments.
Tumor cell recognition by CTL assay 1 Â 10 5 TRP-2 CTL clone (MR7) cells, which has been wellcharacterized in previous reports (Khong and Rosenberg, 2002; Liu et al., 2003) , were plated with 1 Â 10 5 target cells in 96-well, round-bottom plates in 200 ml of complete medium. After 18-24 h of incubation at 371C, the supernatant was harvested for detection of IFN-g release using ELISA kits (Endogen, Cambridge, MA, USA). The coefficient of variation of intra-and interassay of an ELISA assay was less than 10%.
Immunoselection by TRP-2 CTL
The CTL-escape population was generated as described in a previous report (Fisk and Ioannides, 1998) . TRP-2-U373 cells were cultured in the medium without G418 selection for 1 month before immunoselection. Tumor cells to be selected were added at 2 Â 10 6 cells/well to a six-well Falcon plate along with 1 Â 10 6 TRP-2 CTL clone (MR7) cells in a final volume of 6 ml of Ham's F-12/DMEM with high glucose culture medium. After 2 days, the wells were rinsed gently with PBS and the nonadherent cells were removed. Immunoselected cells were then further cultured. The determination of drug resistance was performed 7 days after the initiation of selection with CTLs.
ELISPOT assay
ELISPOT assay kits were supplied from R & D Systems (Minneapolis, MN, USA) and performed as described by the manufacturer's instructions. Responder (R) 1 Â 10 5 patients' PBMC from before and after vaccination were plated in 96-well plates with nitrocellulose membrane inserts coated with capture Ab. Stimulator (S) cells (T2 pulsed TRP-2 180-188 ) were added at the R:S ratio of 1 : 1. After a 24-h incubation, cells were removed by washing the plates four times. The detection Ab was added to each well. The plates were incubated at 41C overnight and the washing steps repeated. After 2-h incubation with streptavidin-AP, the plates were washed. Aliquots (100 ml) of BCIP/NBT chromogen were added to each well to develop the spots. The reaction was stopped after 60 min by washing with water. The spots were scanned and counted with computer-assisted image analysis (Cellular Technology Ltd, Cleveland, OH, USA). When experimental values were significantly different from the mean number of spots against nonpulsed T2 cells (background values), as determined by a two-tailed Wilcoxon rank sum test, the background values were subtracted from the experimental values. The coefficient of variation of intraassay for ELISPOT in our experiments was less than 10%.
Clinical protocol
Recurrent patients with pathological confirmation of grade IV astrocytoma (GBM) were recruited from the Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles. Following surgical resection of their tumors, all patients received a 6-week course of radiation therapy. Vaccinated glioblastoma patients were required to exhibit Karnofsky performance scores of more than 50 and to be free from steroid administration at the time of blood collection and throughout vaccine administration as previously described (Yu et al., 2001) . Fresh single tumor-cell suspension was lysed by 4-5 freeze-thaw cycles. Lysis was monitored by light microscopy and larger particles were removed by centrifugation (10 min at 600 g). Supernatants were then passed through a 0.2 mm filter, and total protein concentration in the tumor lysate was determined by Bio-Rad protein assay kit. Aliquots were frozen at À801C until use. Vaccinated patients received 1-4 Â 10 7 autologous DCs loaded with 150 mg/ml total protein of autologous tumor lysate (vaccine) administered three times starting at approximately 15 weeks postsurgery. Five patients who were both HLA-A2 and TRP-2 positive were selected for this study. PBMC from 1 week before vaccination and 2 weeks after the third vaccination were used to have their TRP-2-specific CTL analysed. Tumors recurred after vaccination in two of five patients (pt .11 and pt. 81). Pt. 11 was treated with temozolomide at the standard dose, which was 150-200 mg/m 2 qd Â 5 days every 28 days, when the tumor recurred after the vaccinations. Serial MRI scans were performed every 2-3 months for the pt. 11. All of the patients provided informed consent to treatments and associated monitoring. The studies were carried out in accordance with research protocols approved by the Institutional Review Board of the CedarsSinai Research Institute.
Statistical analysis
Student's t tests were used. A difference of Po0.05 was considered significant.
